Cabometyx plus Tecentriq led to improved progression-free survival compared with novel hormonal therapy in patients with metastatic castration-resistant prostate cancer.
The European Medicines Agency has validated a type II variation application for the first-line combination of nivolumab and cisplatin-based chemotherapy for adult patients with unresectable or metastatic urothelial carcinoma.